Finance

Lists
Why is TNXP down 5.24%?
Dive Deeper
TNXP:NASDAQ
Tonix Pharmaceuticals Holding Corp
$ 9.23
-5.24%
(-0.51) 1D
$ 9.27
+0.46% (+0.042)
After hours
Closed: 10-р сарын 1, 16:00:00 (GMT-4)  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for TNXP...
Open
$ 9.65
High
$ 9.69
Low
$ 9.19
Mkt. cap
158.30 сая
Avg. vol.
463.15 мян
Volume
475.03 мян
52-wk high
$ 25.40
52-wk low
$ 9.19
EPS
-$ 12.92
Beta
1.74
Shares outstanding
17.15 сая
No. of employees
142
Open
$ 9.65
High
$ 9.69
Low
$ 9.19
Mkt. cap
158.30 сая
Avg. vol.
463.15 мян
Volume
475.03 мян
52-wk high
$ 25.40
52-wk low
$ 9.19
EPS
-$ 12.92
Beta
1.74
Shares outstanding
17.15 сая
No. of employees
142
News stories
From web sources and news partners
Profile
Tonix Pharmaceuticals is a pharmaceutical company based in Chatham, New Jersey that focuses on repurposed drugs for central nervous system conditions and as of 2020 was also pursuing a vaccine for COVID-19 and a biodefense project. Wikipedia
About Tonix Pharmaceuticals Holding Corp
CEOSeth Lederman
Employees142
Founded2007
HeadquartersBerkeley Heights, Нью Жерси, Америкийн Нэгдсэн Улс
Sector-
Analyst ratings
Based on 3 analysts giving stock ratings to TNXP in the past 3 months
Strong buy
Buy
3
Hold
0
Sell
0
12-month forecast
Based on 3 Wall Street analysts offering 12 month price targets for TNXP in the last 3 months.
Highest
Current $ 9.23
$ 65.00 (+604.23%)
Average
$ 38.00 (+311.70%)
Lowest
$ 22.00 (+138.35%)
Analyst
Recommendation
Action
Price target
Projected
Date
James Molloy
Alliance Global Partners
Buy
Reiterated
$ 65.00
+604.2%
09/28/2026
Stacy Ku
TD Cowen
Buy
Maintained
$ 22.00
+138.4%
08/10/2026
Tiago Fauth
Raymond James
Buy
Reiterated
$ 27.00
+192.5%
08/10/2026
Robert LeBoyer
Noble Financial
Buy
Reiterated
$ 37.00
+300.9%
03/16/2026
Last report
2026 оны 8-р сарын 10
Fiscal period
Q2 2026
EPS / Est. (USD)
-$ 2.47 / -$ 2.62
+5.58%beat
Revenue / Est. (USD)
13.54 сая / 7.72 сая
+75.38%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
2025 оны 9-р сар
2025 оны 12-р сар
2026 оны 3-р сар
2026 оны 6-р сар
Revenue
3.29 сая
5.39 сая
6.88 сая
13.54 сая
Cost of goods sold
1.37 сая
1.06 сая
1.58 сая
703.00 мян
Cost of revenue
1.37 сая
1.06 сая
1.58 сая
703.00 мян
Research and development expenses
9.29 сая
16.94 сая
18.21 сая
19.42 сая
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
25.70 сая
35.68 сая
28.62 сая
35.96 сая
Operating expense
34.99 сая
52.62 сая
46.84 сая
55.38 сая
Total operating expenses
36.36 сая
53.68 сая
48.42 сая
56.08 сая
Operating income
-33.07 сая
-48.29 сая
-41.54 сая
-42.54 сая
Other non operating income
-174.00 мян
32.00 мян
-3.00 мян
551.00 мян
EBT including unusual items
-32.01 сая
-46.91 сая
-40.19 сая
-40.55 сая
EBT excluding unusual items
-32.01 сая
-46.91 сая
-40.19 сая
-40.55 сая
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-32.01 сая
-46.91 сая
-40.19 сая
-40.55 сая
Net profit margin
-972.95%
-870.32%
-584.38%
-299.41%
Earnings per share
-3.70
-3.98
-2.93
-2.47
Interest and investment income
1.23 сая
1.34 сая
1.35 сая
1.43 сая
Interest expense
-
-
-
-
Net interest expenses
1.23 сая
1.34 сая
1.35 сая
1.43 сая
Depreciation and amortization charges
-
-
-
-
EBITDA
-32.61 сая
-47.80 сая
-40.98 сая
-41.92 сая
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
Google аппс